Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double- blind, placebo controlled study of larazotide acetate for the prevention of celiac disease reactivation by gluten challenge in celiac subjects in remission(1) were presented by Daniel Leffler, MD from Beth Israel Deaconess Medical Center at the DDW today.

Celiac disease affects approximately 1% of individuals in the United States and Europe or approximately 6.5 million individuals. The only accepted therapy for the disease is a strict gluten-free diet; however, the response to therapy is poor or incomplete in up to 30% of patients. Dietary non-adherence is the chief cause of persistent or recurrent symptoms(2). Over time, 30-50% of individuals are unable to maintain a strict gluten-free diet. Additionally, a gluten-free diet fails to induce clinical or histological improvement in 7-30% of celiac patients and such a lack of response should trigger a systematic evaluation(3). These facts suggest that there is a need for therapeutic modalities beyond dietary modification.

Alba's study, the first Phase IIa trial in celiac disease and the first to assess dosing requirements for larazotide acetate, was designed to evaluate the safety, tolerability and efficacy of multiple doses of larazotide acetate in celiac disease subjects during a 2 week gluten challenge. The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who had a confirmed biopsy diagnosis for celiac disease and were in compliance with a gluten-free diet for at least six months prior to enrollment as demonstrated by a negative serology test of anti-transglutaminase (tTG). Patients were randomized into seven drug-treated and placebo groups and challenged three times a day w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Ala. , Aug. 19, 2014  The Alabama Supreme ... that patients can sue drug makers who mislead doctors into ... harmful side‑effects.  The case is Weeks v. Wyeth, and the ... makers in that same case last year. Heninger Garrison Davis ... represent the patient in the case, Danny Weeks . ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 ... the "Pharmaceutical Contract Manufacturing - Global Strategic Business ... This report analyzes the worldwide markets for Pharmaceutical Contract ... Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms ... (Syrups, Suspensions, Gels, Creams & Ointments). The ...
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... Sept. 23, 2011 Henry Ford Hospital became the third ... Stimulation (DBS) procedure inside an Intraoperative Magnetic Resonance Imaging scanner, ... the neurosurgical toolbox," says Jason M. Schwalb, M.D., Director of ... "Although awake surgery with brain mapping is still ...
... Science, Inc., creators of the Basis™ B1 band, today announced ... and gaming luminaries including Kevin Colleran, Charles and Kai Huang, ... Chris Verplaetse to join the company,s executive team as vice ... launched later this year, the Basis B1 band is the ...
Cached Medicine Technology:DBS Operation for Parkinson's Disease Performed Inside iMRI 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 3
(Date:8/20/2014)... 2014 The National Association of ... million Science Education Partnership Award (SEPA) grant from ... collaborative project with the Hispanic Communications Network (HCN) ... This collaborative NIH R25 program has been established ... diversity among health professionals by recruiting and interviewing ...
(Date:8/20/2014)... August 20, 2014 New Jersey’s Medical ... of an estimated tens of thousands of patients in ... Bill A3525—a bill that would expand the list of ... own cannabis—earlier this summer by State Assemblywoman Linda Stender, ... quality marijuana is growing. , To help fill the ...
(Date:8/20/2014)... Verndale is pleased to announce their ... exclusive list ranking the fastest-growing private companies in America. ... their yearly percentage revenue growth over a three-year period. ... Inc. 5000 list where it ranked number 2,855. , ... clients a wide range of digital marketing services including ...
(Date:8/20/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... System in Hermiston, Ore. The top executive search ... has recently placed more than 900 healthcare executives into ... a progressive, not-for-profit healthcare organization serving a population of ...
(Date:8/20/2014)... 2014 Biosimilars, which are similar ... through an abbreviated process, could reap billions in ... Information Services, Inc.’s (AIS) Specialty Pharmacy News offers ... the Food and Drug Administration’s (FDA) recent acceptance ... approval. , Drugmaker Sandoz said July 24 that ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
... TUESDAY, Jan. 4 (HealthDay News) -- President Barack Obama ... gives the U.S. Food and Drug Administration unprecedented powers ... The Food Safety Modernization Act, first passed by the ... represents the first significant strengthening of the nation,s food ...
... (HealthDay News) -- Levels of schooling may affect treatment and ... called acute ST-segment elevation myocardial infarction (STEMI), a new study ... attack, STEMI occurs when the coronary artery is totally blocked, ... In the new study, Dr. Rajendra H. Mehta, from ...
... N.C. A tiny light source and sensors at the ... to identify pre-cancerous cells in the lining of the esophagus. ... tested on patients during a clinical trial at the University ... promise of being a less invasive method for testing patients ...
... for the 2013 America,s Cup has been announced, a study ... smooth sailing. The study was published recently in the journal ... survey completed by sailors, researchers at Rhode Island Hospital have ... two types of boats -- dinghies (small boats with crews ...
... , TUESDAY, Jan. 4 (HealthDay News) -- Elderly people ... dementia, researchers have found. The new study included more ... dental examination and a psychiatric assessment. Compared with participants who ... or no teeth were much more likely to have experienced ...
... patients with osteoarthritis (OA) are likely not following standard ... Researchers noted physicians were prescribing medications for pain and ... weight loss plans or exercise programs to OA patients. ... January 2011 issue of Arthritis Care & Research ...
Cached Medicine News:Health News:Obama to Sign Bill to Improve U.S. Food Safety 2Health News:Obama to Sign Bill to Improve U.S. Food Safety 3Health News:Higher Education May Benefit Some Heart Attack Patients 2Health News:Detecting esophageal cancer with light 2Health News:Watch out for that boom 2Health News:Watch out for that boom 3Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 2Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 3
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: